Back

Results from the LEADER cardiovascular outcomes trial.

28 August 2017 (12:55 - 13:05)
Organised by:
Congress Presentation Part of: GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm? Diabetes, dysglycaemia and metabolic syndrome ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Mansoor Husain

University of Toronto, Toronto (Canada)

3 More presentations in this session

Presentation thumbnail
Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Professor L. Ryden (Stockholm, SE)
Presentation thumbnail
Translating trials into practice – Clinical implications .
Professor M. Pfeffer (Boston, US)
Presentation thumbnail
Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?
Professor L. Ryden (Stockholm, SE) Professor M. Pfeffer (Boston, US) Doctor M. Husain (Toronto, CA)

Access the full session

Session thumbnail
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

The Event

Event poster

ESC Congress 2017

28 August 2017 12:55 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources